GO
Loading...

Enter multiple symbols separated by commas

Celgene Corp

More

  • Demonstrators are shown during a rally in Athens, Greece, June 29, 2015.

    Managers discuss Greece, volatility and how to play it

  • June 30- U.S. stocks shed some of their early gains on Tuesday as nervous investors wondered whether last-minute talks would produce a bailout deal that would keep Greece in the euro. German Chancellor Angela Merkel told lawmakers she did not expect any new developments, appearing to dash hopes of a deal before Greece defaults on a 1.6 billion euro payment to the...

  • June 30- Wall Street was set to open higher on Tuesday, a day after the Dow and the S&P 500 registered their worst session since October, as investors hoped Greece would strike a last-minute deal to avoid an exit from the euro zone. Greece is hours away from defaulting on a 1.6 billion euro repayment to the International Monetary Fund. U.S. corporations have limited...

  • Early movers: PNR, CAG, GE, FIT, JUNO, GM & more Tuesday, 30 Jun 2015 | 7:57 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Juno, Celgene's $1B cancer-fighting deal: CEO Tuesday, 30 Jun 2015 | 7:15 AM ET
    Juno, Celgene's $1B cancer-fighting deal: CEO

    Hans Bishop, Juno Therapeutics CEO, discusses the company's strategic collaboration with Celgene to develop advance immunotherapies for patients with cancer and autoimmune diseases.

  • Celgene places $1B bet on Juno Therapeutics Tuesday, 30 Jun 2015 | 1:45 AM ET

    Biotech giant Celgene has invested $1 billion in Juno Therapeutics in a move to that backs experimental cancer treatments, the FT reports.

  • Your first trade for Tuesday Monday, 29 Jun 2015 | 6:19 PM ET
    Fast Money Final Trade:  COST, NXPI, RNF & SAVE

    The "Fast Money" traders give their final trades of the day.

  • After-hours buzz: Juno, Apollo Education & more Monday, 29 Jun 2015 | 5:35 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Check out the companies making headlines after the bell Monday: Juno, Apollo Education & more.

  • June 29- Celgene Corp said it would invest about $1 billion in Juno Therapeutics Inc to partner in the development and marketing of immunotherapies for the treatment of cancer and autoimmune diseases. Celgene will pay Juno about $150 million upfront and buy about 10 percent of Juno's shares at $93 each, almost double of Juno's closing price on Monday.

  • June 29- Celgene Corp and Juno Therapeutics Inc said they signed a deal to develop and commercialize immunotherapies for the treatment of cancer and autoimmune diseases. Juno will receive about $150 million upfront, and will sell 9.1 million shares of its common stock at $93 each to Celgene, the companies said on Monday. Shares of Juno were up 61 percent in...

  • June 29- Celgene Corp and Juno Therapeutics Inc said they signed a deal to develop and commercialize immunotherapies for the treatment of cancer and autoimmune diseases. Juno will receive about $150 million upfront, and will sell 9.1 million shares of its common stock at $93 each to Celgene, the companies said on Monday. Shares of Juno were up 61 percent in...

  • Portfolio Playbook: Buy the chips Thursday, 18 Jun 2015 | 3:23 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Portfolio Playbook: Buy the chips

  • Lightning Round: Huge deals ahead for this group Wednesday, 17 Jun 2015 | 7:59 PM ET
    Mad Money Lightning Round

    Jim Cramer sees that this group is ready for some major deals, as he gives his take on caller favorite stocks.

  • As tech stocks stall, these names may break out Wednesday, 10 Jun 2015 | 1:55 PM ET

    Technology, one of the hottest areas in the six-year bull market has hit a standstill in 2015. Here are the stocks that could buck the trend.

  • After-hours buzz: Five Below, FireEye & more Wednesday, 3 Jun 2015 | 5:48 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Check out the companies making headlines after the bell Wednesday: Five Below, FireEye & more.

  • After BMY's drop, cancer drug stocks set to move? Monday, 1 Jun 2015 | 5:00 AM ET
    Attendees walk through the lobby at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. (File Photo).

    The stock-moving news flow started early out of the American Society of Clinical Oncology meeting in Chicago.

  • Biotech investors up big amid bubble talk Thursday, 28 May 2015 | 9:56 AM ET
    Biotech

    Some view skyrocketing biotech stocks as a bubble, but hedge funds are riding optimism in the sector to monster gains—for now.

  • Here's how to play weak Q2 earnings season Monday, 18 May 2015 | 7:39 AM ET
    Delta Airlines planes sit at Terminal 4 at John F. Kennedy Airport in New York.

    Negative revenue growth will continue to dog investors in Q2 and Q3, analyst Mike Thompson says. Here's what to do about it.

  • This biotech stock is a bargain: Strategist Wednesday, 13 May 2015 | 2:45 PM ET
    Biotech

    Options expert Stacey Gilbert explains why Celgene is trading at a discount to its peers.

  • Investors were waiting for news that could move share prices from many bigger companies including Bristol-Meyers Squibb Co, Amgen Inc and Celgene Corp. Hot topics at the American Society of Clinical Oncology conference in Chicago will include immuno oncology and CAR-T cell therapies. Shares in Juno Therapeutics Inc, Kite Pharma Inc, BlueBird Bio Inc and...